A randomized clinical trial of the Unified Protocol for Transdiagnostic treatment of emotional and gastrointestinal symptoms in patients with irritable bowel syndrome: evaluating efficacy and mechanism of change by Mohsenabadi, H. et al.
Contents lists available at ScienceDirect
Journal of Psychosomatic Research
journal homepage: www.elsevier.com/locate/jpsychores
A randomized clinical trial of the Uniﬁed Protocol for Transdiagnostic
treatment of emotional and gastrointestinal symptoms in patients with
irritable bowel syndrome: evaluating eﬃcacy and mechanism of change
Hamid Mohsenabadia, Zahra Zanjania,⁎, Mohammad Javad Shabania, Abbas Arjb
a Department of Clinical Psychology, Medical Faculty, Kashan University of Medical Science, Kashan, Iran
bDepartment of Gastroenterology, Kashan University of Medical Sciences, Kashan, Iran
A R T I C L E I N F O
Keywords:
Anxiety
Depression
Stress
Emotion Regulation
Irritable Bowel Syndrome
Transdiagnostic Treatment
Uniﬁed Protocol
Randomized Clinical Trial
A B S T R A C T
Objective: The aim of this randomized controlled trial was to evaluate the eﬃcacy of Uniﬁed Protocol (UP) for
transdiagnostic treatment of psychological problems, such as anxiety, depression, and stress, and treating the
intensity of gastrointestinal symptoms in individuals with Irritable Bowel Syndrome (IBS). Another aim of the
study was to test whether emotion regulation mediates the eﬀect of UP.
Methods: Among 91 patients diagnosed with IBS (using ROME III criteria), 64 patients were eligible to parti-
cipate in the study based on the inclusion/exclusion criteria. These patients were randomly assigned to either an
intervention group (n=32) that participated in 12 weekly UP treatment sessions or to a wait-list control group
(n=32). All patients completed the Depression, Anxiety, and Stress Scale (DASS-42), Emotion Regulation
Questionnaire (ERQ), and Gastrointestinal Symptoms Rating Scale (GSRS) pre- and post-intervention. The data
were analyzed with SPSS 20.0 software.
Results: The results of intention-to-treat (ITT) analysis indicated a signiﬁcant decrease in depression, anxiety,
stress, and gastrointestinal symptoms, as well as signiﬁcant improvements in emotion regulation scores in the
intervention group post intervention. All results were signiﬁcant at P < .001. Mediation analyses indicated that
changes in emotion regulation mediated the eﬀect of UP on changes in emotional and gastrointestinal symptoms.
Conclusion: UP was eﬀective and inﬂuential in emotion regulation among the intervention group and caused a
decline in emotional and gastrointestinal symptoms. Hence, this intervention is promising, but larger RCTs are
needed to more investigate its eﬃcacy. Future studies could also examine the eﬃcacy of the UP in other medical
conditions with co-occurring psychological conditions.
The study is registered at the irct.ir database under registration number IRCT2017010431765N1.
1. Introduction
Irritable bowel syndrome (IBS) is the most prevalent functional
gastrointestinal disorder, aﬀecting 10%–22% of the adult population
[1]. IBS is characterized by abdominal discomfort, changes in bowel
habits, and pain without any structural abnormalities. Since there are
no clear-cut diagnostic signs of IBS, its diagnosis is based on clinical
manifestations [2]. This syndrome is widespread among all countries
and socio-economic classes, and it is more prevalent among women
than men [3]. Indirect eﬀects of IBS include social isolation, employee
absenteeism, and ﬁnancial problems, and it may put undue ﬁnancial
pressure on the society's economy [4]. In Iran, the overall incidence of
IBS has been reported to be between 1.1% and 25% [5].
Many studies have conﬁrmed that various psychological disorders
are widely prevalent among patients with IBS [6, 7]. IBS is more closely
associated with anxiety and depression than with other psychiatric
disorders [8]. It has been reported that patients IBS suﬀer from gen-
eralized anxiety disorder, depression, or panic disorder [9, 10]. Psy-
chological comorbidities, especially depression and anxiety in IBS, are
correlated with personal suﬀering, decreased social functioning, re-
duced treatment adherence, poor quality of life [11].
Moreover, patients with depression and anxiety may apply in-
eﬃcient or passive coping skills for emotion regulation [12]. Previous
studies have indicated that many patients with IBS suﬀer from emotion
dysregulation and are not able to identify and express their emotions
may be at risk of somatoform disorders and may have more intense
physical symptoms, as they are unable to distinguish emotions from
physical states [13].
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Pharmacological and psychological treatments have both been
shown to be eﬀective in reducing the symptoms of IBS, but they have
limitations. Pharmacological treatments can temporarily alleviate IBS
symptoms [14], they are often expensive and may have negative side
eﬀects such as dry eyes, dry mouth, urinary retention, sedation,
drowsiness, palpitations, and visual changes, as well as a risk of over-
dose (whether unintentional or deliberate) and cardiac arrhythmias
[15, 16]. On the other hand, the psychological treatments used for IBS
include cognitive behavioral therapy (CBT); hypnosis; and mindfulness-
based, psychodynamic, and interpersonal therapies [17–19]. Psycho-
logical treatment improves physical symptoms severity, depression, and
anxiety, overall with small to moderate eﬀect sizes [20]. They involve
numerous protocols for targeting speciﬁc disorders despite a high rate
of comorbidity in patients.
To improve treatment, integrative treatments are recommended.
The Uniﬁed Protocol for the transdiagnostic treatment of emotional
disorders focuses on targeting emotional dysregulation as a common
maladaptive coping strategy across diﬀerent emotional disorders. UP is
a cognitive behavioral intervention including 5 core components that
target temperamental features, especially neuroticism and resulting
emotion dysregulation, underlying all depressive, anxiety and asso-
ciated disorders [21]. In a systematic review, improvements in emo-
tional regulation was associated with improvements in depression and
anxiety [22]. Various researches have examined the eﬃcacy of trans-
diagnostic treatments in comorbid emotional disorders and improving
the emotion regulation of patients with comorbid anxiety and depres-
sion [23–26].
The reasons for examining the usage of UP for the treatment of IBS
include the high frequency of emotional disorders comorbidities in IBS
and the eﬃcacy of UP in targeting emotion regulation through emo-
tional exposure and skills training. Consequently, the purpose of this
paper is twofold: 1) examining the eﬃcacy of UP in treating psycho-
logical problems such as anxiety, depression, and stress in patients
suﬀering from IBS and 2) examining the mediating role of emotion
regulation in relationship between UP and reduce emotional disorder
and IBS symptom severity.
2. Methods
This study was a parallel-group randomized clinical trial with in-
tervention and waitlist control group to assess the eﬃcacy of the UP in
patients with IBS. The population consisted of all patients with IBS in
Shahid Beheshti Hospital of Kashan who referred to the hospital in
2017 and gastroenterology experts conﬁrmed that they had IBS based
on ROME III criteria. All participants completed the informed consent
form. The inclusion criteria consisted of: receiving the diagnosis of IBS
based on Rome III criteria, 18–40 age range, Having emotional symp-
toms based on cut-oﬀ-score≥15 in the depression and anxiety subscale
of DASS-42, having at least a high school degree (because the UP re-
quired activity of individuals, and they had to do some assignment at
home which needed their motivation, vigor, and their ability in iden-
tifying thoughts and emotions), to be willing and consent for partici-
pating in the study. Exclusion criteria consisted of: receiving other
psychological treatments since last year and during the research pro-
cess, having bowel surgery, psychotic characteristics or suicidal
thoughts, organic mental disorder, history of drug abuse or drug de-
pendence.
The present study was approved by the ethics committee of Kashan
University of Medical Science with the number of
IR.KAUMS.REC.1395.100. Written informed consents obtained from all
participants. The study is registered at the irct.ir database under re-
gistration number IRCT2017010431765N1.
2.1. Participants
Among 91 patients with IBS who referred to the Shahid Beheshti
Fig. 1. Flow diagram of the study
Note: ITT= intention-to-treat.
H. Mohsenabadi et al. Journal of Psychosomatic Research 113 (2018) 8–15
9
Hospital of Kashan in 2017, 64 individuals identiﬁed as eligible ac-
cording to inclusion and exclusion criteria (Fig.1). Participants were
randomly assigned to the wait-list control and intervention group by
using a random number table. They were asked not to make any
changes in their medication during the study. The intervention group
received 12 weekly sessions of UP treatment which each session lasted
2 h.
Recruitment for the study started in July 2017 and ended in October
2017. All participants completed the assessments prior to the inter-
vention and immediately following the ﬁnal visit.The evaluators and
analysts were blinded to randomize assignment.
2.2. Intervention protocol
The intervention was based on Barlow et al. protocol [27]. The aim
of UP is to foster emotional regulation by cultivating the 5 core pro-
cesses of UP, including: 1) to increase emotional awareness at the
present moment, 2) cognitive ﬂexibility, 3) to prevent maladaptive
emotion-driven behaviors and emotional avoidance, 4) to increase
awareness and tolerance of physical sensations, and 5) to practice in-
teroceptive and situational exposure (Table 1).
2.3. Therapists and treatment integrity
UP treatment was run by an MSc in clinical psychology with three
years of therapy experience and one PhD in clinical psychology with
6 years of experience. Treatment adherence was monitored weekly by a
supervisor with PhD. of clinical psychology who was also certiﬁed in
the UP. Supervisor used the Therapist Adherence Rating Scale (Barlow,
personal communication, 2017) as a ﬁdelity form.
2.4. Control condition
The wait-list control group in this study received no psychological
treatment, but all study participants received their usual pharmaceu-
tical treatment (See Table 2). The wait-list control group received
written information about the causes, symptoms of IBS, an explanation
of how IBS is diagnosed, and diets associated with IBS. UP treatment
was oﬀered to the wait-list control group after the end of the study.
3. Measurements
3.1. Depression, anxiety and stress scale (DASS-42)
This 42-item scale is a self-report instrument that developed by
Lovibond and Lovibond [28]. Items are rated on a four-point scale
(ranged from 0 to 3) and reﬂect the frequency and severity of emotional
experiences over the last week. The DASS assess the severity of three
psychological conditions of anxiety, depression, and stress. Studies re-
ported good validity and reliability for DASS-42 [28]. It demonstrated
good reliability in the current study (Cronbach's α=0.87 for depres-
sion subscale; α=0.82 for anxiety subscale; α=0.78 for stress
subscale).
3.2. Emotion regulation questionnaire (ERQ)
This questionnaire was developed by Gross and John [29] to mea-
sure emotion regulation strategies. This scale is made up of 10 items
consisting of 4 suppression items and 6 reappraisal ones. Each item
must be answered on a 7- point scale ranging from 1 (strongly disagree)
to 7 (strongly agree). The reliability and validity of the ERQ have been
conﬁrmed [29]. This scale demonstrated good reliability in the current
study (Cronbach's α=0.94 for reappraisal subscale and 0.89 for sup-
pression).
3.3. Gastrointestinal symptoms rating scale (GSRS)
This scale is made up of 15 questions combined in to 5 symptom
clusters which depict the most common signs of gastrointestinal dis-
orders. These questions assess the severity of gastrointestinal symptoms
based of a 7 -point Likert scale ranging from (1) means no discomfort to
(7) means very severe discomfort. Higher values indicate the severity of
symptoms [30]. The GSRS shown good reliability in the current study
(Cronbach's α=0.82).
Table 1
Description of the components of the UP in the intervention group.
Components Session
1. Motivation enhancement 1
2. Psychoeducational and treatment rationale 2
3. Emotion awareness training 3–4
4. Cognitive reappraisal 5
5. Emotion avoidance 6
6. Emotion-driven behaviors and emotional avoidance 7
7. Awareness and tolerance of physical sensations 8
8. Interoceptive and situational exposure 9–11
9. Relapse prevention 12
Table 2
Participants' characteristics of intent-to-treat sample for each group at baseline.
Variables Study participants
All (n=64) UP (n= 32) control (n=32) P- Value
Age, mean (± SD) 30.9(± 5.2) 31.2(± 4.7) 30.6(±5.7) .68a
Sex, n (%)
Male 26(40.6) 12(37) 14(44) .61b
Female 38(59.4) 20(63) 18(56)
Marital status, n (%)
Single 21(32.8) 10(31) 11(34) .79b
Married 43(67.2) 22(69) 21(66)
Education, n (%)
High school 28(43.8) 15(47) 13(41) .85b
Bachelor'’s degree 21(32.8) 9(28) 12(38)
Master'’s degree 10(15.6) 5(16) 5(16)
Ph.D. 5(7.8) 3(9) 2(6)
Disease duration,
mean (± SD)
6.1(± 1.9) 6.2(± 1.9) 6.0(± 1.9) .61a
Drug utilization, n
(%)
Anticholinergics 18(24.7) 8(21.6) 10(27.8) .15b
Antispasmodics 18(24.7) 9(24.3) 9(25)
Antidepressants 6(8.2) 3(8.1) 3(8.3)
Antinauseants 7(9.6) 4(10.8) 3(8.3)
Antibiotics 5(6.8) 3(8.1) 2(5.6)
Laxatives 13(17.8) 7(18.9) 6(16.7)
Antidiarrheal
agents
6(8.2) 3(8.1) 3(8.3)
Psychosocial
characteristics
Depression (DASS-
42)
23.8(5.8) 23.7(6.4) 23.8(5.2) .93a
Anxiety (DASS-42) 21.7(6.3) 21.5(6.3) 22.0(6.5) .72a
Stress (DASS-42) 24.6(3.7) 24.9(3.4) 24.4(4.1) .64a
Cognitive
reappraisal(ERQ)
14.5(4.6) 14.0(4.4) 15.0(4.9) .39a
Expressive
suppression
(ERQ)
19.0(3.3) 19(3.5) 19.1(3.2) .88a
Symptom severity
(GSRS)
55.3(6.9) 54(7.2) 56.6(6.5) .13a
P=P value; SD=Standard deviation.
a Independent samples t-test.
b Chi-square test.
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3.4. Statistical analysis
Kolmogorov–Smirnov test and Levene's test were used to determine
normality and equality of variance. Chi-square test and independent t-
test were used for examination of diﬀerences between groups in de-
mographic characteristics. The analyses were based on the intention-to-
treat principle (ITT). Data analyses of primary and secondary outcomes
were conducted using linear mixed models (LMMs). LMMs analyses
were utilized to examine time ×group and main time and group eﬀects
between the UP and wait-list groups on outcome measures at pre-
treatment and post-treatment. Time, condition, and a time×condition
were considered as ﬁxed eﬀects and participant identiﬁer was con-
sidered as a random eﬀect, allowing for participant intercepts to vary
by individual and model run with unstructured covariance type. All
available data were used because ﬁtting linear mixed models does not
require imputation of missing data. Dropping data were handled using
the last observation-carried-forward (LOCF) method. Estimates from
the LMMs analyses were also used to calculate treatment eﬀect sizes
from pre to post treatment. Also, Eﬀect sizes for UP versus WLC mean
using Cohen's d were calculated using the diﬀerence between two
means divided by a standard deviation for the data [31]. The mediation
analysis was tested by multiple regression analyses, controlling for age,
sex and education. Sobel test was calculated to test signiﬁcance of the
mediation eﬀect [32]. The data were analyzed using Statistical Package
for the Social Sciences version 20.0 (SPSS Inc., Chicago, IL, USA) and a
P < .05 considered as statistically signiﬁcant.
4. Results
4.1. Participants' characteristics
Fig. 1 is illustrating CONSORT diagram of participant ﬂow during
the study. According to Figs. 1, 64 patients were eligible regarding
inclusion/exclusion criteria (rate of eligibility: 64/91=70%). Seven
patients dropped out of the intervention group (dropout rate 7/
32=22%) and 4 patients dropped out of the wait-listed control con-
dition (dropout rate 4/32= 13%; adherence rate 53/64=83%). Pa-
tients that completed the intervention group (n=25) attended an
average of 10.80 (SD=0.81) out of the sessions.
The demographic characteristics of the participants are presented in
Table 2. No signiﬁcant diﬀerence was observed between two groups for
any demographic variables, indicating that randomization was suc-
cessful. The mean age of participants was 30.9 ± 5.2, and 59.4%
participants were female. The most of patients were married (n= 43)
and 21 of them were single. Most of them had a high school or bachelor
degree. The mean diseases duration was 6.1 (SD=1.9) years among all
participants. According to cutoﬀ values on the DASS-42 [28], partici-
pants had severe depressive symptoms (mean= 23.8 > 21), extremely
severe anxiety (mean= 21.7 > 20), and moderate stress (be-
tween19–25; mean=24.6). There were no signiﬁcant diﬀerences be-
tween the intervention and wait-list control groups regarding drug
therapy (χ2= 21.77; p= .15) (See Table 2).
4.2. Eﬀects of treatment on primary treatment outcomes
4.2.1. Depression
The LMMs analysis of the depression scores demonstrated a sig-
niﬁcant time×group interaction, F(1, 99.350)= 15.15, p < .001.
Between group comparisons indicated signiﬁcant diﬀerences between
the treatment conditions at post-treatment t(62)= 2.644, p < .01,
d= 1.23. Within-group comparisons indicated a signiﬁcant diﬀerence
for the UP condition from pre- to post-treatment t(31)= 6.33,
p < .001, d=1.01. Signiﬁcant diﬀerences were not found for the
wait-list condition from pre- to post-treatment t(31)= 0.424, p= .674,
d= 0.05. These ﬁndings indicated that treatment UP had a large, sig-
niﬁcant impact on reducing depression over the treatment period Ta
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Table 3.
4.2.2. Anxiety
The analysis of the anxiety scores revealed a signiﬁcant time ×
group interaction, F(1, 105.01)= 14.21, p < .001. Between group
comparisons indicated signiﬁcant diﬀerences between the treatment
conditions at post-treatment t(62)= 2.440, p < .01, d= 0.97. Within-
group comparisons indicated a signiﬁcant diﬀerence for the UP condi-
tion from pre- to post-treatment t(31)= 7.295, p < .001, d= 1.18.
Signiﬁcant diﬀerences were not found for the wait-list condition from
pre- to post-treatment t(31)= 1.143, p= .26, d=0.11. These ﬁndings
indicated that treatment UP had a large, signiﬁcant impact on reducing
anxiety in patients suﬀering from IBS.
4.2.3. Stress
The LMMs analysis of the stress scores revealed a signiﬁcant time ×
group interaction, F(1, 111.01)= 24.26, p < .001. Between group
comparisons indicated signiﬁcant diﬀerences between the treatment
conditions at post-treatment t(62)= 3.931, p < .001, d= 1.03.
Within-group comparisons indicated a signiﬁcant diﬀerence for the UP
condition from pre- to post-treatment t(31)= 7.706, p < .001,
d= 1.15, but not for the wait-list condition t(31)=−0.579, p= .56,
d= 0.08. These ﬁndings indicated that treatment UP had a large, sig-
niﬁcant impact on reducing stress in patients with IBS.
4.2.4. Symptom severity
Symptom severity scores revealed a signiﬁcant time × group in-
teraction, F(1, 95.460)= 8.77, p < .004. Between group comparisons
indicated signiﬁcant diﬀerences between the treatment conditions at
post-treatment t(62)= 2.96, p < .02, d=1.33. Within-group com-
parisons indicated a signiﬁcant diﬀerence for the UP condition from
pre- to post-treatment t(31)= 6.016, p < .001, d= 1. Signiﬁcant
diﬀerences were not found for the wait-list condition from pre- to post-
treatment t(31)= 1.44, p= .15, d=0.26. These ﬁndings indicated
that treatment UP had a large, signiﬁcant impact on reducing symptom
severity over the treatment period.
4.3. Eﬀects of treatment on the proposed mediators
4.3.1. Cognitive reappraisal
The LMMs analysis of the cognitive reappraisal scores demonstrated
a signiﬁcant time × group interaction, F(1, 109.33)= 33.79,
p < .001. Between group comparisons indicated signiﬁcant diﬀerences
between the treatment conditions at post-treatment t(62)=−4.776,
p < .001, d=1.32. Within-group comparisons indicated a signiﬁcant
diﬀerence for the UP condition from pre- to post-treatment t
(31)=−7.199, p < .001, d= 1.34. Signiﬁcant diﬀerences were not
found for the wait-list condition from pre- to post-treatment t
(31)=−0.756, p= .455, d=0.06. These ﬁndings indicated that
treatment UP had a large, signiﬁcant impact on improving cognitive
reappraisal over the treatment period.
4.3.2. Suppression
Suppression scores demonstrated a signiﬁcant time× group inter-
action, F(1, 104.79)= 12.29, p < .001. Between group comparisons
indicated signiﬁcant diﬀerences between the treatment conditions at
post-treatment t(62)= 2.39, p < .02, d= 1.04. Within-group com-
parisons indicated a signiﬁcant diﬀerence for the UP condition from
pre- to post-treatment t(31)= 5.175, p < .001, d= 0.92. Signiﬁcant
diﬀerences were not found for the wait-list condition from pre- to post-
treatment t(31)= 0.848, p= .40, d=0.09. These ﬁndings indicated
that UP had a large impact on reducing suppression in patients with IBS
over the treatment period.
4.4. Mediation analyses
The eﬀects of UP on depression, anxiety and stress through changes
in emotion regulation was tested based on Baron and Kenny approach
[33]. Baron and Kenny (1986) proposed a four-step approach by several
regression analyses. 1) The treatment groups should predict therapeutic
change (Path C). 2) The treatment groups should predict change in the
mediator (Path a). 3) Change in the mediator should predict therapeutic
change (Path b). 4) The eﬀect of treatment groups on change in the
Fig. 2. Direct and Indirect eﬀects of UP on change in
emotional (stress, anxiety, and depression) and gas-
trointestinal symptoms from pre to post-intervention
via change in the cognitive reappraisal.
Notes ⁎p < 0.05; a: Full Mediation (a relationship
between independent and dependent variable (C)
that was initially signiﬁcant has to become insignif-
icant in the presence of the mediator (C′).
Model covariates: age, sex and education ⃰.
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outcome should be decreased when change in the mediator is con-
trolled (Path C′). Change scores for each of mediator and outcomes
variables demonstrated the diﬀerence between the score at posttest and
pretest. And treatment groups were TAU (coded 1) and UP (coded 2)
consequently, separate linear regression analyses were used to examine
mediating role of emotion regulation (Figs. 2 and 3).
4.4.1. Emotion regulation as mediator of treatment outcome
Results of the mediation analyses were presented in Figs. 2 and 3. In
both models age, sex and education were controlled as covariates. In
the mediation model assessing the role of the cognitive reappraisal in
mediating the relationship between UP and therapeutic change, there
was a signiﬁcant indirect eﬀect (Fig. 2). The results indicated full
mediation, as the direct eﬀect between UP and therapeutic change was
no signiﬁcant when accounting for the cognitive reappraisal. Similarly,
the mediation model 2 assessing the suppression as a mediator in-
dicated suppression fully mediated the relationship between UP and
gastrointestinal symptoms change. However, the UP direct eﬀect on the
emotional disorders decreased but yet was signiﬁcant when including
the suppression in the model, indicating partial mediation (Fig. 3).
Consequently, the Sobel test was used to examine whether this decrease
is signiﬁcant. The Sobel test for this mediation model showed sup-
pression having a signiﬁcant mediating eﬀect between treatment con-
dition and emotional symptoms (Z=−3.25, P < .001 for depression,
Z=−2.88, P < .003 for anxiety, Z=−3.56, P < .001 for stress).
These results indicated that change in emotion regulation mediated the
eﬀect of UP on change in emotional symptoms and gastrointestinal
symptoms severity.
5. Discussion
The main purpose of this study was to investigate the eﬃcacy of UP
on anxiety, depression, stress, emotion regulation, and IBS symptoms.
The obtained results revealed that UP was beneﬁcial for patients with
IBS and could decrease anxiety, depression, stress, and gastrointestinal
symptoms in addition to improving emotion regulation. Although only
a few studies have been conducted on the eﬀects of UP on patients with
IBS, the results of this study were in line with those of research on
similar disorders. For instance, our ﬁndings are consistent with the
results of previous research on the eﬃcacy of UP on the emotional
problems of patients with functional gastrointestinal disorders and
psychosomatic patients [34]. Furthermore, the results of the present
study indicated that UP could be eﬀective in reducing gastrointestinal
symptoms. This result was consistent with Johary's study about de-
creasing IBS symptoms via UP [35]. Previous research has reported the
eﬀects of UP on emotional disorders [23, 36–41].
A component of UP considered in this paper is interoceptive ex-
posure. Patients suﬀering from IBS are more sensitive to visceral sen-
sations than healthy individuals [42, 43]. Visceral sensitivity, which is
highly associated with severe IBS symptoms, anxiety, and depression
[44–46], is common among IBS patients [47]. According to previous
research, visceral sensitivity mediated between gastrointestinal symp-
toms, anxiety, and neuroticism [45, 46], and the mediating role of
visceral senses may improve the results of IBS treatments [48]. Patients
with IBS may beneﬁt from interventions that aim at intermediary psy-
chological procedures, including visceral sensitivity [49]. Accordingly,
interoceptive exposure has been conﬁrmed to be eﬀective in visceral
sensitivity reduction for IBS treatment [48, 50]. Therefore, UP treat-
ment with interoceptive exposure can have an eﬀect on the severity of
IBS symptoms, anxiety, depression, and stress.
Another purpose of the study was to investigate whether emotion
regulation mediates the eﬀect of UP on changes in emotional and gas-
trointestinal symptoms in patients with IBS. The results indicated the
cognitive reappraisal fully mediated eﬀect UP on the therapeutic
change in all of the emotional (stress, anxiety, and depression) and
gastrointestinal symptoms. According to results, the suppression par-
tially (not fully) mediated eﬀect of UP on changes in emotional symp-
toms but fully mediated the relationship between UP and gastro-
intestinal symptoms change. This study found that UP improved both
cognitive reappraisal and expressive suppression that the latter ap-
peared to be more relevant in mediating the eﬀects of UP on psycho-
logical and gastrointestinal outcomes in IBS. It seems that UP help IBS
patients to identify and express their emotions and it leads them to have
less intense psychological and physical symptoms. Results of the
Fig. 3. Direct and Indirect eﬀects of UP on change in
emotional (stress, anxiety, and depression) and gas-
trointestinal symptoms from pre- to post-interven-
tion via change in the suppression.
Notes ⁎ P < 0.05; a: Partial mediation (implies that
a relationship that was initially signiﬁcant in the
absence of mediator continues to be signiﬁcant even
in the presence of the mediator); b: Full Mediation (a
relationship between independent and dependent
variable (C) that was initially signiﬁcant has to be-
come insigniﬁcant in the presence of the mediator
(C′).
Model covariates: age, sex and education.
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mediation analyses were consistent with the literature, which suggests
that emotion regulation is an important construct in the psycho-
pathology and IBS [13, 44]. Research showed that diﬃculties with
emotion regulation are fundamental to the growth and maintenance of
psychopathology [51, 52]. It was found that the maladaptive strategies
(e.g., suppression and avoidance) to regulate emotion were associated
with a wide range of emotional disorders and is directly related to
anxiety and depression [53]. It can be concluded that emotion dysre-
gulation is an important factor of the development of psychological
disorders in individuals with IBS. In fact, in the majority of psycholo-
gical disorders, there is at least one symptom of emotional disturbance
[54].
The UP particularly targets deﬁcits in emotion regulation and lead
to the choice of more adaptive emotion regulation techniques both
through skills practice and emotion exposures. The goal of UP is to
reduce co-occurring emotional disorders by improved emotion regula-
tion [27]. The present study results provided the support for UP model.
Emotional awareness (EA) as the ﬁrst step in the process of emotion
regulation is correlated with a range of emotional disorders. Patients
with psychosomatic disorders, especially IBS, have lower EA or sup-
press their emotion [55]. EA as a component of UP enables the in-
dividual to distinguish between various thoughts, physical sensations,
and behaviors that inﬂuence their discomfort [15]. Research indicated
that EA improved the results of medical treatment of IBS [56]. The
purpose of this component is identifying an individual's method of re-
acting and responding to their emotions, promoting nonjudgmental
awareness, and encouraging individuals to concentrate on the present
moment via mindfulness skills. Mindfulness allows the individual to
distinguish between various thoughts, physical sensations, and beha-
viors that inﬂuence their discomfort [15].Research has indicated that
adding EA training to medical treatments may lead to superior results
among patients with IBS [56], including a substantial decrease in
symptoms and an improved quality of life. Consequently, it seems that
UP can decrease the eﬀects of emotional disturbances and ameliorate
gastrointestinal symptoms by increasing EA through emotion regulation
skills.
In addition to EA, another component of UP is cognitive reappraisal.
Cognitive reappraisal is a main emotion regulation strategy [55]. The
importance of cognitive appraisal and ﬂexibility for treating patients
with IBS has been veriﬁed in previous studies [57]. Among patients
with IBS, a positive relationship has been traced between cognitive
appraisal and abdominal pain and discomfort [58]. Anxiety is also as-
sociated with cognitive appraisal among these patients [59]. In one
study [60], catastrophizing as a cognitive appraisal had a direct re-
lationship with the severity of participants' IBS symptoms, and it
mediated the relationship between anxiety and symptom severity in
patients with IBS. In this regard, emphasis on reducing catastrophizing
may produce positive results in IBS treatment [61]. Hence, UP is ef-
fective in the cognitive appraisal by improving emotion regulation skills
which, in turn, leads to decreased emotional symptoms of patients with
IBS.
In summary, emotional regulation mediated the improvements in
both emotional and gastrointestinal symptoms. This is important and
suggests that targeting this common mechanism can be valuable for
patients with co-occurring physical and emotional symptoms.
5.1. Limitations and suggestions for future research
There are several limitations in this study. First, the sample size was
small, which makes it diﬃcult to generalize the results. Second, the
study did not include a follow-up with participants to examine the
continuation of the intervention eﬃcacy. Third, the study lacked an
“active comparison” group. Fourth, the p-value that is derived from the
Sobel test in smaller sample sizes will not be an accurate estimate of the
true p-value.
For future research, it is recommended that a similar study be
conducted that includes a follow-up stage. An active or CBT group
could also be added for comparison with the group receiving UP for
treatment. Researchers could investigate which of the UP modules is
most clinically eﬀective in treating patients suﬀering from gastro-
intestinal diseases.
6. Conclusion
There are several comorbid psychological conditions for patients
with IBS, such as anxiety and depression. In this study, UP was used for
the transdiagnostic treatment of emotional disorders in individuals with
IBS. UP focuses on the common pathologic factors among various di-
agnostics. The results of the present study conﬁrmed that the UP was
eﬃcacious for improving emotion regulation; it helped participants
deal with emotional problems and caused a reduction in gastro-
intestinal symptoms related to IBS. Hence, this protocol can be applied
as a complementary treatment to other pharmacotherapies and medical
treatments for patients with IBS.
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